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Abstract 
Background 
Screening and Brief Interventions for alcohol are an effective public health measure to tackle 
alcohol-related harm, however relatively few countries across the European Union (EU) have 
implemented them widely. This may be due to a lack of understanding of the specific financial 
implications of such policies within each country. 
Methods 
A novel meta-modelling approach was developed based on previous SBI cost-effectiveness models 
for four EU countries. Data was collected on the key factors which drive cost-effectiveness for all 28 
EU countries (mean per capita alcohol consumption, proportion of the population to be screened 
over a 10-year SBI programme; per capita alcohol-attributable mortality; per capita alcohol-
attributable morbidity; mean cost of an alcohol-related hospitalisation and mean SBI-delivery staff 
cost). Regression analysis was used to fit two meta-models estimating net programme costs and 
quality-adjusted life-years (QALYs) gained, to calculate cost-effectiveness estimates specific to each 
EU country.  
Results 
Costs are dependent upon the proportion of the population covered by the screening programme, 
the country-specific per capita mortality and morbidity rate and the country-specific costs of GP care 
and hospitalisation. QALYs depend on the proportion of the population screened and per capita 
alcohol consumption. Despite large inter-country variability in factor values, SBI programmes are 
likely to be cost-effective in 24 out of 28 EU countries and cost-saving in about 50% of countries.  
Conclusion 
Implementing national programmes of SBI in primary health care would be a cost-effective means of 
reducing alcohol-attributable morbidity and deaths in almost all countries of the EU. 
 
Key words: Alcohol Consumption, Early Intervention, Primary Health Care, Cost-Effectiveness 
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Introduction 
The negative health consequences of excessive alcohol consumption represent a substantial burden 
on health care systems throughout Europe (1,2). One of the key recommended policy approaches to 
target this problem is a programme of screening and brief interventions for heavy drinking in 
primary health care (SBI) (3,4), which has been shown to result in significant reductions in alcohol 
consumption (5,6). The primary health care setting is ideal for SBI as individuals can be screened 
opportunistically when at the practice for other reasons e.g. new patient registration or a standard 
health check, with the intervention taking place as part of a general conversation around the 
patients health (7). 
 
A recent systematic review looking at the cost-effectiveness of SBI programmes concluded that they 
were likely to be cost-effective despite heterogeneity around delivery methods, length of brief 
interventions and outcome measures (8), a finding that a number of subsequent studies have 
echoed (3,9,10). However, the majority of existing studies are from the United Kingdom (UK), United 
States (US) or Australia meaning that the conclusions may not be transferable to other countries, 
including mainland Europe where several nations have already implemented SBI programmes to 
various extents (11). Furthermore, there is evidence that both the costs and potential benefits, and 
thus cost-effectiveness, of SBI is likely to be heterogeneous across Europe and therefore a single 
cost-effectiveness conclusion for the entire region may potentially be inaccurate for the individual 
countries concerned (3,12). Given the importance of alcohol consumption as a risk factor for ill 
health and mortality, the existence of good quality cost-effectiveness evidence tailored to each 
European country is essential if uptake of SBI amongst primary health care practitioners is to be 
promoted by healthcare services and governments. 
 
Clinical guidelines  for Europe recommend that health services should provide funding for primary 
health care based SBI, and that practitioners should receive training and support to be able to carry 
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these out (13) and both the World Health Organisation and Organisation for Economic Co-operation 
and Development (OECD) have recommended more widespread implementation (3,14). However, in 
practice uptake varies considerably across Europe and overall fewer than 10% of heavy drinkers are 
currently identified in this setting (15,16). Government support and financial incentives for SBI in the 
UK have led to high general practitioner (GP) familiarity with standardised screening tools and brief 
intervention practices (16,17), and, in the case of Scotland, the delivery of 272,000 brief 
interventions between 2008 and 2012 (18), but only a handful of other European countries including 
Sweden, Finland and Italy have invested significant efforts in the institutionalisation of SBI 
programmes, supported by national laws, policies or guidelines (11). In most of the EU, GPs are 
poorly informed and feel uncomfortable about discussing alcohol with their patients, and as a result 
the uptake of SBI remains low (16,19,20). 
 
This analysis aims to bridge the gap between the existing evidence around cost-effectiveness of SBIs 
and the large number of European countries for which no cost-effectiveness studies have been 
performed. We have previously used the Sheffield Alcohol Policy Model (SAPM) to estimate costs 
and effectiveness of SBI in Italy, the Netherlands, Poland and England (7,21,22).  Whilst the gold-
standard approach for other EU countries may be to adapt or develop similar, highly detailed, 
models to assess the potential impacts of SBI programmes, such models are generally costly and 
time-consuming to develop and require data to parameterise them which may not exist for all 
countries. Here we extend this existing analysis using a meta-modelling approach to provide an 
estimate of the cost-effectiveness of carrying out a national SBI programme in each EU member 
state. 
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Methods 
Modelling Screening and Brief Interventions using the Sheffield Alcohol Policy Model  
Our approach was based on pre-existing SBI modelling work using SAPM, which was developed to 
model the health impact of a range of government policies on alcohol (23,24).  SAPM was used to 
model the effect of carrying out a ten year programme of delivering SBIs to all patients registering 
with a new GP in four countries: England, Italy, Poland and the Netherlands (7,21,22). In each case 
the model was adapted to reflect the best available country-specific data; however, all 4 models 
utilised the same structure, outcome measures and perspective (that of the healthcare sector).  
Results were harmonised across the 4 models by converting all costs to Euros using the Organisation 
for Economic Co-operation and Development (OECD) purchasing power parities (PPPs) (25) and 
inflated to 2013 prices using the country-specific harmonised inflation rate (26). All cost and QALY 
outcomes were discounted at 3.5% per year (27). The cost-effectiveness outcomes of the four 
individual models are presented in Table 1. 
 
INSERT TABLE 1 ABOUT HERE 
 
Developing the meta-model 
A meta-model is a simplified version of a complex model, which can be used to generate predictions 
about the outputs of that model (28,29). In the present context, the development of a meta-model 
enables cost-effectiveness results to be predicted for countries beyond the four already modelled in 
detail. To construct the meta-model it was necessary to identify a set of key numbers or factors 
which summarised the key model inputs and captured the aspects likely to affect the cost-
effectiveness of SBI programmes between countries.  Factors which did not have a common 
definition across all 4 countries, such as measures of binge drinking, or for which country-specific 
data was unlikely to be available for other EU countries, such as the distribution of drinking across 
the population, were excluded.  
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Six factors were identified that fulfilled the above criteria: 1) The mean alcohol consumption of the 
modelled population (grams of pure alcohol per day); 2) The proportion of the population screened 
over the modelled ten year programme; 3) The per capita mortality rate from all alcohol-related 
health conditions combined; 4) The per capita morbidity rate for all alcohol-related health conditions 
combined; 5) The mean cost per hospitalisation for an alcohol-related health condition; 6) The per-
minute cost of the health professional who delivers the SBI. The baseline values for these six factors 
for the four SAPM model adaptations are shown in Table 1. 
 
In order to efficiently establish the impact of varying these six factors on the model outputs, in terms 
of the net cost of the SBI programme and total Quality-Adjusted Life Years (QALYs) gained, we 
employed a fractional factorial design methodology (29). Within each country, the value of each 
factor was varied across two levels, the observed value and an alternative value chosen to cover the 
potential range of values across the remaining 24 EU countries. For example, GP costs in the UK are 
among the highest in Europe so the alternative value chosen was 50% of this level. New 
combinations of input factors, selected to efficiently cover the decision space, were run through the 
country-specific models in order to estimate the net costs and QALY gains of the SBI programme for 
each alternative scenario. These alternative scenarios can be conceptualised as pseudo-countries, 
with each country model run a total of 16 times (including once with the original, baseline, factor 
values) to give 64 combinations of model inputs and outputs from which to fit the meta-models. A 
detailed description of meta-model development and the selection of levels can be found in the 
ODHIN project report (10). 
 
Fitting the meta-model 
For each of these 64 pseudo-countries, results were divided by the number of eligible adults (those 
aged 18+) in each country to give per capita values. The impact of the six factors on the modelled 
cost-effectiveness was then assessed by developing ordinary least squares (OLS) regression models 
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for each country, separately for both cost and QALY output. Selection of included independent 
variables for each model was undertaken using log-ratio tests and by comparing Bayesian 
Information Criteria (BIC) and adjusted R-squared values. All models were fitted and analysed in 
Stata 12 (30). 
 
Data collection to inform the six meta-model parameters 
Data was collected to inform the six factor parameters for all 28 EU member states. Collected values 
are presented in Table S1 in the Supplementary Material. Large databases from organisations such 
as the WHO and Eurostat were used as much as possible in order to ensure standardisation of data 
between countries.  If a choice was available, data from 2008 (or as close to 2008 as possible) was 
preferred to match the input data for the 4 existing country models. Data for Italy, Poland and the 
Netherlands was gathered in the same way as for the other EU countries, to act as a comparison 
between the data gathering methods used for this analysis and the much more extensive data 
collection process used for the country-specific models.  
 
1) Alcohol consumption: In order to maintain consistency with the input data used in the 4 original 
country models, self-reported alcohol consumption data, rather than consumption estimates 
derived from national-level sales data were preferred. Mean consumption of alcohol in grams per 
day was therefore calculated from the Dynamo Health Impact Assessment model (DYNAMO-HIA), 
which is based upon survey data from individual EU countries (31). DYNAMO-HIA estimates the 
number of individuals in each age group of the population of a country that fall into five categories 
for daily drinking (0-0.25g, 0.25-20g, 20-40g, 40-60g, >60g). Mean g/day consumption was calculated 
by multiplying the number of individuals in each group by the category mean (32) and dividing by 
the total population. Twelve EU countries were missing from the DYNAMO-HIA database due to lack 
of survey data. A value for alcohol consumption was estimated for these countries by using data 
from a geographically adjacent country with similar levels of alcohol consumption according to WHO 
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sales data (33). As we do not have detailed data on patterns of alcohol consumption or levels of 
heavy episodic drinking associated with acute health harms such as alcohol poisoning, mean 
consumption acts as a proxy in the model for overall levels of harmful drinking. 
 
2) The proportion of the population screened over ten years was based upon internal migration data 
from the Internal Migration Around the Globe (IMAGE) project (34). This study identified proportions 
of the population in countries of the world who moved address within a one or five year period. To 
extrapolate to ten years it was assumed that the probability of moving in each year was independent 
of previous years and that every move would result in registering with a new GP practice. Data was 
not available for Luxembourg, which was assumed to be the same as for France. 
 
3) Per capita mortality rate for alcohol-related health conditions was obtained from Eurostat for all 
countries (35). 
 
4) Per capita morbidity rate for alcohol-attributable conditions was obtained from the WHO as the 
sum of inpatients plus day-cases per 1000 population (2), divided by an adjustment coefficient to 
avoid double counting repeat admissions from the same individual (36). Three countries had data for 
inpatients but not day-cases, in which case the mean day-case value for all countries was added to 
the inpatient value. Four countries were missing data, in which case values were used from 
neighbouring countries with similar costs of hospitalisation (see below). 
 
5) Mean costs of hospitalisation for each country were obtained from Eurostat by dividing hospital 
health expenditure  by total number of inpatient discharges for all health conditions (35).  Missing 
values for five countries were obtained from 2008 values for geographically and economically similar 
countries. 
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6) Per minute costs of health professionals delivering the SBI were based on GP salary and hours 
worked per week, and were obtained from three different sources; the OECD, the International 
Labour Organisation (ILO) and Kroneman et al (3739). These values did not take into account 
administration costs or training. All costs were inflated to 2013 prices in local currency and 
converted to euros using PPPs (25,26). 
 
Calculating cost-effectiveness of SBI for all EU countries 
Total incremental costs and QALYs per capita for SBI versus control were calculated for each EU 
country from the collated data using the fitted cost and QALY meta-models. An incremental cost-
effectiveness ratio (ICER = costs/QALYs) was then derived for each country. In the absence of a single 
common threshold for cost-effectiveness across all 28 countries we applied the standard UK 
threshold of £20000/QALY (approx 26000), adjusted using PPPs, for all countries (27).  
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Results 
The coefficients from the final fitted OLS regression models for costs and QALYs per capita are 
presented in Table 2. Costs are dependent upon the proportion of the population screened, the 
mortality rate per capita and GP cost, and are inversely correlated with morbidity rate per capita and 
the mean cost per hospitalisation. This means that in the long-term and from a whole healthcare 
system perspective, SBIs are more expensive overall in countries where there is high mortality from 
alcohol-attributable conditions but low morbidity, as preventing morbidity is cost-saving whereas 
preventing mortality actually leads to higher costs as surviving patients may subsequently become 
ill, using additional healthcare resources. Similarly, SBI programmes are more expensive in countries 
where GP consultations are expensive, but hospital care is cheap, as the initial SBI delivery phase is 
high, while the future cost savings produced by the beneficial effect of SBI on morbidity diminish as 
costs of hospital care go down. Health gains, in terms of additional QALYs, are dependent only upon 
mean alcohol consumption and the proportion of the population screened, none of the other factors 
showing a significant relationship. For both models, interaction terms between input factors were 
tested but none proved to be significant. 
 
INSERT TABLE 2 ABOUT HERE 
 
The model coefficients were used together with the collected data on the six factors to calculate 
mean costs and QALYs per capita and associated ICERs for each EU country. A national SBI 
programme is estimated to be cost-effective in 24 of 28 EU countries and dominates (i.e. is more 
effective and less costly than) a scenario with no SBI delivery in 14 countries (see Table 3 for a 
complete list of country-specific results). Figure 1 shows these results on the cost-effectiveness 
plane, with 95% confidence intervals around both costs and QALY estimates, illustrating that 
countries group into distinct clusters. The greatest health gains are estimated to be delivered in 
northern European countries such as the UK and Scandinavia, with SBI policies being generally cost-
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saving. In Mediterranean countries such as Spain, France and Greece, SBI shows a more moderate 
QALY gain, but is also generally cost-saving. Eastern European countries however tend to have both 
the lowest QALY gains and the highest costs and this group includes the 4 nations: Bulgaria, Croatia, 
Estonia and Romania, for whom SBIs are not estimated to be cost-effective. In general we observe 
that the cost-effectiveness of SBI programmes shows a positive correlation with the GDP of a 
country. 
 
INSERT TABLE 3 & FIGURE 1 ABOUT HERE 
 
Comparison of meta-model results for cost-effectiveness in Italy, Poland, the Netherlands and the 
UK/England using either values from the 4 country-specific models or from the standardised factor 
values collected for all 28 countries demonstrate some notable discrepancies. For Italy the results 
are fairly similar whichever factor values are used. However, for the Netherlands and the 
UK/England, costs are vastly underestimated and QALYs are over-estimated using collected factor 
values rather than baseline factor values results, and consequently the policies are estimated to be 
more cost-effective. Conversely, for Poland, QALYs are under-estimated and costs are roughly the 
same meaning that cost-effectiveness is lower when using collected rather than baseline factor 
values. Note that these discrepancies arise primarily from differences in the input data rather than 
uncertainty in the regression model. The biggest differences arise from variation in the estimates of 
GP costs and the proportion of the population screened. As GP costs for the collected values were 
based upon salary alone and didnt include administration or training costs, a sensitivity analysis was 
performed whereby they were increased by five-fold. However, despite no longer dominating the 
control scenario, SBI remained a cost-effective or highly cost-effective option in 20 of the 28 EU 
countries (see Table S3 in the Supplementary Material) indicating that inaccuracy in estimating GP 
cost is unlikely to change the decision about whether or not to implement SBI. Sensitivity analyses 
altering the proportion of the population screened were also performed. Increasing the proportions 
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(e.g. screening at next GP consultation rather than screening at new GP registration) tended to 
increase cost-effectiveness, with all 28 nations becoming cost-effective or cost-saving (see Table S4 
in the Supplementary Material), whereas reducing the proportion screened by 50% tended to 
reduce cost-effectiveness meaning that SBI was no longer cost-effective for the majority of Eastern 
European countries(see Table S5 in the Supplementary Material). This indicates that in lower GDP 
countries, a cost-effective SBI policy relies upon a sufficient proportion of the population being 
screened.  
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Discussion 
The results presented here indicate that implementing a national programme of SBI is likely to be an 
effective and cost-effective option for almost all EU countries, despite large inter-country variability 
in healthcare costs, alcohol consumption and alcohol-attributable health outcomes. Although in the 
short-term the interventions tend to be costly (21,22), savings are accrued over the medium-long 
term (5-30 years) due to reduced hospital admissions, making SBI cost-saving overall in half of the 
countries. Intervention effectiveness appears to be correlated with GDP, whilst costs are inversely 
correlated, meaning that SBI is more likely to be cost-effective in countries with higher GDP.  
 
Previous economic analyses of SBI in Europe have generally focussed on evaluating its cost-
effectiveness in one or two individual countries, and have shown that SBI is likely to be cost-effective 
in the UK, Italy, Poland, the Netherlands, the Czech Republic and Germany (8,40). The one exception 
to this is a study by Chisholm and others, which compared the cost-effectiveness of different alcohol 
interventions, including SBI, across different WHO geographic regions, including 3 broad regions of 
Europe (12). In contrast with our results they found that cost-effectiveness was higher in the poorer 
eastern European regions than in the richer northern and western European region. However, their 
costing analysis covered intervention implementation costs only and did not incorporate the cost 
savings accrued due to the reduction in alcohol-attributable hospital admissions, which have a 
disproportionate effect in richer countries. In addition, Chisholm used disability-adjusted life years 
(DALYs) to assess intervention effects rather than QALYs, which can produce quite different 
estimates of effectiveness (41). Given this fuller treatment of relevant costs and the provision of 
estimates for individual countries, we believe that the meta-model results presented here represent 
the most accurate source of current information about the cost-effectiveness of SBI for the majority 
of EU countries. 
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There are several limitations to the modelling process that should be taken into account when 
interpreting the results. Firstly, the model does take drinking patterns within each country into 
account, instead depending simply on the measure of mean consumption in grams per day. Binge 
drinking has a different profile of risks than drinking a consistent amount of alcohol every day (42), 
yet the model is unable to distinguish between drinking patterns and overall consumption. One issue 
with incorporating such information into any international model is that currently there is a lack of 
standardisation between countries in how different drinking patterns should be defined (43), 
meaning that data from different individual-level surveys often cannot be easily compared. 
Secondly, the model shares those limitations inherent in SAPM; for example it does not account for 
heterogeneity in response to SBI, either within subgroups of the population of a country or between 
countries. If the effectiveness of SBIs were to vary according to the drinking patterns of the recipient 
this may bias the results presented here, although there is some evidence that SBIs work equally 
well across a range of countries and contexts (44).  It is also important to note that the uncertainty 
estimates presented here are likely to be under-estimates of the true level of uncertainty associated 
with the cost-effectiveness results, as they can only incorporate the statistical uncertainty within the 
meta-model regression and are unable to take account of either parameter uncertainty or structural 
uncertainty. An additional consideration is our use of a single cost-effectiveness threshold applied to 
all countries. The true value of any intervention depends on the absolute scale of the problem it 
seeks to address as well as the benefit associated with the available alternative investment options, 
both of which will vary between countries.  Policy makers are therefore advised to consider these 
factors alongside the disaggregated costs and benefits and the overall cost-effectiveness figure. 
 
A final limitation of the model is that the results not only assume that all internal migration events 
result in new GP registration, but also assume 100% implementation of SBI in newly registering 
patients. This is unlikely to happen in practice as currently there are many barriers to 
implementation of large-scale national programmes, including GP attitudes and a general lack of 
15 
 
training, resources or incentives (11,45). The result is that the number of beneficiaries and hence the 
overall costs and benefits of a national SBI programme at the population level would be lower than 
predicted by the meta-model. The sensitivity analysis indicates that if only 50% of the expected 
population is screened then SBI may no longer be a cost-effective option for the less wealthy 
European countries. However, the low level of internal migration (used as a proxy for new GP 
registration) in eastern Europe is one of the factors that contributes to poor cost-effectiveness 
results in the meta-model and it may be that SBI would be better implemented in a different manner 
in such countries to improve population uptake e.g. perhaps at next GP consultation instead.  
 
There are several avenues for further research, both to improve the accuracy of the meta-model 
predictions and to increase knowledge about the costs, effectiveness and challenges inherent in SBI 
implementation in Europe. Many of the model inputs are based on data that would be much 
improved by standardisation to aid inter-country comparisons. Currently factors such as mortality 
and morbidity rates are fairly comparable, but good quality data on self-reported alcohol 
consumption is lacking in many countries, as are standardised costs for time spent with healthcare 
professionals such as GPs. Further research assessing barriers to implementation in different EU 
countries would also be useful if uptake of SBI is to be encouraged. Of course, any country wishing to 
implement SBI on the basis of these results would be advised to evaluate their impact, as there have 
been very few effectiveness trials in Europe and local factors may affect the achieved effectiveness 
in unpredictable ways. 
 
In summary, SBI is likely to be cost-effective throughout the EU, except in  those countries with the 
lowest GDPs. Whilst the findings presented here do not furnish decision makers with the same level 
of detail or precision as a bespoke prospective policy appraisal, they provide valuable insight into the 
potential costs and benefits of SBI policies and may help to guide future policy and research 
priorities.  
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Whilst there are challenges, countries should consider the best ways of developing and 
implementing SBI programmes in their context, which may include screening patients at their next 
primary health care appointment or in other settings. Future research should aim at reducing 
existing uncertainties and resolving implementation problems, which together should facilitate 
increased uptake of SBI in Europe. 
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Key points 
x Programmes of Screening and Brief Interventions (SBI) in primary health care are an 
effective measure to reduce alcohol-related harm, but are not widely implemented across 
Europe. A lack of understanding of the likely health and budget impacts specific to each 
country may be a significant barrier to more widespread uptake. 
x This study provides country-specific estimates of costs and effects from national SBI 
programmes in all 28 EU countries. Results demonstrate that widespread national 
programmes of SBIs are likely to be cost-effective in 24 of 28 EU countries with 50% of 
countries estimated to save money following their introduction 
x These results provide strong support for widespread adoption of large scale SBI programmes 
across Europe although some consideration should be given to methods of implementation, 
particularly in less wealthy countries 
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Tables 
Table 1: Baseline factor values and SAPM adaptation results 
Country 
Mean 
consumption 
(g/day) 
Alcohol-
Attributable 
mortality rate 
(per capita) 
Alcohol-
Attributable 
morbidity rate 
(per capita) 
Mean cost of 
hospitalisatio
n () 
Cost of 
GP 
(/min) 
Population 
coverage 
(%) 
Net 
programme 
cost  ( per 
capita) 
QALYs 
gained per 
capita 
ICER 
(/QALY) 
England 15.6 0.00456 0.0527 7698 3.85 39.8 5.29 0.00117 4533 
Nether-
lands 
12.8 0.00240 0.0468 8583 3.01 35.9 -0.58 0.00088 Dominates
* 
Poland 7.0 0.00439 0.0319 2810 0.28 67.2 1.69 0.00107 1584 
Italy 12.2 0.00404 0.0327 5854 0.96 69.8 1.53 0.00135 1135 
*Dominates  the programme is both health-improving and cost-saving compared to no SBI delivery 
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Table 2: Cost and QALY regression model coefficients and goodness-of-fit statistics 
  
Factor 
Cost regression model QALY regression model 
Coefficient 
Standard 
Error 
p 
Value 
Coefficient 
Standard 
Error 
p Value 
Mean Consumption -   0.0000601 0.000009 0.000 
% Population 
Screened 
5.52 2.77 0.051 0.00203 0.000198 0.000 
Mortality Rate Per 
Capita 
1400.87 378.32 0.000 - 
  
Morbidity Rate Per 
Capita 
-102.59 44.66 0.025 - 
  
Mean 
Cost/Hospitalisation 
-0.00124 0.000207 0.000 - 
  
GP Cost 3.918 0.286 0.000 -   
Constant -0.996 3.191 0.756 -0.000726 0.000191 0.000 
Adjusted R-Squared 0.7917   0.6236   
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Table 3: Costs, QALYs, ICERs and cost-effectiveness thresholds predicted for all EU countries using 
the meta-model 
Country 
Costs  
( per 
capita) 
QALYs  
(per capita) 
ICER 
(/QALY) 
Cost-effectiveness 
threshold () 
Cost-effectiveness  
(WHO guidelines) 
Using baseline factor values 
England 7.72 0.00102 7574 26873 Cost-effective 
Italy 1.66 0.00142 1168 24139 Cost-effective 
Netherlands 0.70 0.00077 903 25705 Cost-effective 
Poland 3.20 0.00106 3021 13109 Cost-effective 
Using collected factor values 
Austria -2.07 0.00117 -1767 24541 Cost-saving 
Belgium -1.05 0.00158 -664 25027 Cost-saving 
Bulgaria 10.89 0.00059 18499 11497 Not cost-effective 
Croatia 6.49 0.00033 19921 15984 Not cost-effective 
Cyprus -2.16 0.00075 -2884 21709 Cost-saving 
Czech Republic 2.98 0.00055 5457 16030 Cost-effective 
Denmark -4.53 0.00188 -2408 32482 Cost-saving 
Estonia 7.10 0.00027 26549 17690 Not cost-effective 
Finland 2.29 0.00168 1363 28743 Cost-effective 
France -0.77 0.00120 -641 25237 Cost-saving 
Germany 2.05 0.00124 1650 23999 Cost-effective 
Greece -0.93 0.00091 -1020 20681 Cost-saving 
Hungary 7.94 0.00104 7632 13974 Cost-effective 
Ireland -6.94 0.00101 -6860 28322 Cost-saving 
Italy 1.38 0.00127 1086 24139 Cost-effective 
Latvia 8.70 0.00055 15890 16474 Cost-effective 
Lithuania 8.85 0.00083 10680 14792 Cost-effective 
Luxembourg -5.97 0.00120 -4970 28135 Cost-saving 
Malta -1.10 0.00071 -1544 19068 Cost-saving 
Netherlands -5.93 0.00151 -3928 25705 Cost-saving 
Poland 3.34 0.00034 9784 13109 Cost-effective 
Portugal -0.13 0.00083 -150 19162 Cost-saving 
Romania 7.26 0.00023 31888 12549 Not cost-effective 
Slovakia 3.46 0.00033 10619 16101 Cost-effective 
Slovenia 0.69 0.00029 2347 19582 Cost-effective 
Spain -3.47 0.00070 -4968 22013 Cost-saving 
Sweden -5.02 0.00157 -3192 30916 Cost-saving 
United Kingdom -3.98 0.00213 -1872 26873 Cost-saving 
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Figure 1: The estimated impact of national programmes of SBI for different EU countries with 95% confidence intervals.  
 
